|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CIART |
Gene summary for CIART |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CIART | Gene ID | 148523 |
| Gene name | circadian associated repressor of transcription | |
| Gene Alias | C1orf51 | |
| Cytomap | 1q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8N365 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 148523 | CIART | LZE7T | Human | Esophagus | ESCC | 6.43e-06 | 5.27e-01 | 0.0667 |
| 148523 | CIART | LZE24T | Human | Esophagus | ESCC | 9.40e-10 | 3.42e-01 | 0.0596 |
| 148523 | CIART | P2T-E | Human | Esophagus | ESCC | 1.17e-24 | 3.37e-01 | 0.1177 |
| 148523 | CIART | P4T-E | Human | Esophagus | ESCC | 8.95e-10 | 3.84e-01 | 0.1323 |
| 148523 | CIART | P5T-E | Human | Esophagus | ESCC | 1.11e-02 | 7.33e-02 | 0.1327 |
| 148523 | CIART | P8T-E | Human | Esophagus | ESCC | 6.97e-04 | 2.76e-02 | 0.0889 |
| 148523 | CIART | P10T-E | Human | Esophagus | ESCC | 9.11e-22 | 4.85e-01 | 0.116 |
| 148523 | CIART | P12T-E | Human | Esophagus | ESCC | 2.64e-31 | 6.67e-01 | 0.1122 |
| 148523 | CIART | P15T-E | Human | Esophagus | ESCC | 3.99e-03 | 2.63e-01 | 0.1149 |
| 148523 | CIART | P16T-E | Human | Esophagus | ESCC | 4.62e-14 | 3.76e-01 | 0.1153 |
| 148523 | CIART | P20T-E | Human | Esophagus | ESCC | 1.05e-02 | 1.71e-01 | 0.1124 |
| 148523 | CIART | P21T-E | Human | Esophagus | ESCC | 2.06e-23 | 5.80e-01 | 0.1617 |
| 148523 | CIART | P23T-E | Human | Esophagus | ESCC | 2.72e-08 | 3.82e-01 | 0.108 |
| 148523 | CIART | P24T-E | Human | Esophagus | ESCC | 6.84e-04 | 9.59e-02 | 0.1287 |
| 148523 | CIART | P26T-E | Human | Esophagus | ESCC | 6.83e-28 | 6.41e-01 | 0.1276 |
| 148523 | CIART | P27T-E | Human | Esophagus | ESCC | 9.38e-19 | 5.04e-01 | 0.1055 |
| 148523 | CIART | P28T-E | Human | Esophagus | ESCC | 1.00e-08 | 2.27e-01 | 0.1149 |
| 148523 | CIART | P30T-E | Human | Esophagus | ESCC | 2.85e-04 | 3.90e-01 | 0.137 |
| 148523 | CIART | P31T-E | Human | Esophagus | ESCC | 2.82e-12 | 2.59e-01 | 0.1251 |
| 148523 | CIART | P32T-E | Human | Esophagus | ESCC | 6.76e-04 | 1.63e-01 | 0.1666 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003292215 | Esophagus | ESCC | circadian regulation of gene expression | 48/8552 | 68/18723 | 2.76e-05 | 2.30e-04 | 48 |
| GO:004851118 | Esophagus | ESCC | rhythmic process | 164/8552 | 298/18723 | 6.80e-04 | 3.57e-03 | 164 |
| GO:000762319 | Esophagus | ESCC | circadian rhythm | 119/8552 | 210/18723 | 8.47e-04 | 4.36e-03 | 119 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CIART | SNV | Missense_Mutation | rs377608254 | c.287N>C | p.Arg96Thr | p.R96T | Q8N365 | protein_coding | tolerated(0.1) | possibly_damaging(0.666) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| CIART | SNV | Missense_Mutation | c.62N>G | p.Thr21Ser | p.T21S | Q8N365 | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.754) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CIART | SNV | Missense_Mutation | novel | c.139G>C | p.Asp47His | p.D47H | Q8N365 | protein_coding | deleterious(0) | possibly_damaging(0.696) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| CIART | insertion | Frame_Shift_Ins | novel | c.284_285insTCTTGGT | p.Lys95AsnfsTer9 | p.K95Nfs*9 | Q8N365 | protein_coding | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD | ||
| CIART | insertion | Frame_Shift_Ins | novel | c.285_286insTTGGGAGGGTTTGCATCACGTGGCAGGTGCG | p.Arg96LeufsTer16 | p.R96Lfs*16 | Q8N365 | protein_coding | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD | ||
| CIART | SNV | Missense_Mutation | novel | c.462N>C | p.Gln154His | p.Q154H | Q8N365 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| CIART | SNV | Missense_Mutation | novel | c.752C>T | p.Thr251Ile | p.T251I | Q8N365 | protein_coding | tolerated(0.09) | possibly_damaging(0.571) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| CIART | SNV | Missense_Mutation | c.490N>G | p.Ile164Val | p.I164V | Q8N365 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| CIART | SNV | Missense_Mutation | c.1087A>G | p.Thr363Ala | p.T363A | Q8N365 | protein_coding | tolerated_low_confidence(0.13) | benign(0.005) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| CIART | SNV | Missense_Mutation | rs147269137 | c.865N>A | p.Gly289Ser | p.G289S | Q8N365 | protein_coding | tolerated(1) | benign(0.003) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |